TAG:
diagnostic lab
Review of 2004 Lab Sales Identifies Buyer Interest
CEO SUMMARY: Laboratory acquisition activity was surprisingly high during 2004. One reason is that new buyers appeared in the marketplace. However, all buyers have specific acquisition criteria. When a selling lab meets that criteria, it can expect multiple bidders and a strong purchase p…
Exposed: Who Created Path Lab Condo Scheme
CEO SUMMARY: It wasn’t pathologists and it wasn’t laboratory executives who started this scheme. Anatomic pathology condominium laboratory complexes were conceived by urologists in Florida. Some Texas urologists jumped on the bandwagon early, becoming enthusiastic promoters of the sch…
Linking UroCor Indictments With Specialist Doc Pathology
IS THE TIMING of the criminal indictments of three ex-UroCor executives going to be a fortuitous event for the anatomic pathology profession? I ask this question because the exploding trend of specialist physician groups internalizing anatomic pathology services was slated to be the…
ASCP’s “Molecular Pathology” Certification Now Available
RECOGNIZING the growing importance of molecular pathology, the American Society of Clinical Pathology (ASCP) established a new certification program in this diagnostic specialty. Offered since June 2003, 18 people have passed the examination and can use the designation “MP (ASCP)….
IMPATH Has a Buyer: Genzyme Pays $215 Mil
CEO SUMMARY: Two unexpected things happened in IMPATH’s Chapter 11 bankruptcy action. First, it attracted a buyer willing to pay the premium price of $215 million for its assets. Second, the buyer was not another laboratory company. Rather, it is a new entrant into the oncology diagnost…
“September 8, 2003 Intelligence: Late Breaking Lab News”
Early last week, Laboratory Corporation of America announced an out-of-court settlement in its lawsuit involving its subsidiary, DIANON Systems, Inc. As plaintiff, DIANON had sued five former DIANON employees and their new company, DiaPath LLC. The c…
“State of Industry” Report On Molecular Diagnostics
CEO SUMMARY: Enterprise Analysis Corporation has launched an ambitious survey that will include 150 laboratories performing molecular testing in the United States. Last week it released information about the first 51 labs contacted in this effort. The survey provides an intriguing look at…
Laboratories Sit Squarely Between New Genetics and Today’s Medicine
“Clinical laboratories and pathology groups are at the leading edge of the genetic revolution.” —Rick J. Carlson. CEO SUMMARY: Healthcare futurist Rick J. Carlson believes that knowledge of the human genome will trigger revolutionary…
“Direct-to-Consumer” Ad Runs in New York Times
CEO SUMMARY: Two pioneering advertising campaigns launched in September. Both Myriad Genetics and IMPATH targeted consumers with advertisements about diagnostic testing. In each case, the most vocal response to the advertising came from within the medical community. Within the pathology p…
Lab Testing to Boom During This Decade
CEO SUMMARY: Several recent acquisitions of lab test technology by billion-dollar diagnostics manufacturers reinforce a new reality in the healthcare marketplace: developing new diagnostic tests is faster, cheaper, and more profitable than developing new pharmaceutical products. This simp…
CURRENT ISSUE
Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.